E-64-c
CAS: 76684-89-4
Ref. 3D-FE29622
1mg | A consultar | ||
2mg | A consultar | ||
5mg | A consultar | ||
10mg | A consultar | ||
25mg | A consultar |
Información del producto
- (+)-(2S,3S)-3-((S)-3-Methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl)-2-oxiranecarboxylic acid
- (2S,3S)-3-({(2S)-4-methyl-1-[(3-methylbutyl)amino]-1-oxopentan-2-yl}carbamoyl)oxirane-2-carboxylic acid
- (2S,3S)-3-[[[(1S)-3-Methyl-1-[[(3-methylbutyl)amino]carbonyl]butyl]amino]carbonyl]-2-oxiranecarboxylic acid
- 2-Oxiranecarboxylic acid, 3-[[[(1S)-3-methyl-1-[[(3-methylbutyl)amino]carbonyl]butyl]amino]carbonyl]-, (2S,3S)-
- Brn 6688621
- E 64c
- EP 475 (Enzyme inhibitor)
- Ep 475
- Loxistatin acid
- NSC 694279
- Ver más sinónimos
- Oxiranecarboxylic acid, 3-(((3-methyl-1-(((3-methylbutyl)amino)carbonyl)butyl)amino)carbonyl)-, (2S-(2-alpha,3-beta(R*)))-
- Oxiranecarboxylic acid, 3-(((3-methyl-1-(((3-methylbutyl)amino)carbonyl)butyl)amino)carbonyl)-, (2S-(2alpha,3beta(R*)))-
- Oxiranecarboxylic acid, 3-[[[(1S)-3-methyl-1-[[(3-methylbutyl)amino]carbonyl]butyl]amino]carbonyl]-, (2S,3S)-
- Oxiranecarboxylic acid, 3-[[[3-methyl-1-[[(3-methylbutyl)amino]carbonyl]butyl]amino]carbonyl]-, [2S-[2α,3β(R*)]]-
E-64-c is a potent proteolytic enzyme that is used in the treatment of breast cancer. E-64-c cleaves peptide hormones and bcr-abl kinase, which are involved in the development of cancer cells. It can also be used to inhibit the activity of other enzymes, such as phospholipase A2 and cyclooxygenase. The mechanism behind its action is not known, but it may be due to chemical inhibition or reversible denaturation. Chemotherapy drugs that are used to treat breast cancer include doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone, and vincristine.
Propiedades químicas
Consulta técnica sobre: 3D-FE29622 E-64-c
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.